Literature DB >> 21272013

VMAT2: a dynamic regulator of brain monoaminergic neuronal function interacting with drugs of abuse.

Lee E Eiden1, Eberhard Weihe.   

Abstract

The monoaminergic neuron, in particular the dopaminergic neuron, is central to mediating the hedonic and addictive properties of drugs of abuse. The effects of amphetamine (AMPH) and cocaine (COC), for example, depend on the ability to increase dopamine in the synapse, by effects on either the plasma membrane transporter DAT or the vesicular transporter for monoamine storage, VMAT2. The potential role of DAT as a target for AMPH and COC has been reviewed extensively. Here, we present VMAT2 as a target that enables the rewarding and addictive actions of these drugs, based on imaging, neurochemical, biochemical, cell biological, genetic, and immunohistochemical evidence. The presence of VMAT2 in noradrenergic, serotoninergic, histaminergic, and potentially trace aminergic neurons invites consideration of a wider role for aminergic neurotransmission in AMPH and COC abuse and addiction.
© 2011 New York Academy of Sciences.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21272013      PMCID: PMC4183197          DOI: 10.1111/j.1749-6632.2010.05906.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  90 in total

Review 1.  Experimental genetic approaches to addiction.

Authors:  Aki Laakso; Amy R Mohn; Raul R Gainetdinov; Marc G Caron
Journal:  Neuron       Date:  2002-10-10       Impact factor: 17.173

Review 2.  A novel mechanism of action and potential use for lobeline as a treatment for psychostimulant abuse.

Authors:  Linda P Dwoskin; Peter A Crooks
Journal:  Biochem Pharmacol       Date:  2002-01-15       Impact factor: 5.858

3.  Identification of human vesicle monoamine transporter (VMAT2) lumenal cysteines that form an intramolecular disulfide bond.

Authors:  David S Thiriot; Michael K Sievert; Arnold E Ruoho
Journal:  Biochemistry       Date:  2002-05-21       Impact factor: 3.162

4.  Vesicular neurotransmitter transporters in Huntington's disease: initial observations and comparison with traditional synaptic markers.

Authors:  M Suzuki; T J Desmond; R L Albin; K A Frey
Journal:  Synapse       Date:  2001-09-15       Impact factor: 2.562

5.  Tyrosine hydroxylase- and/or aromatic L-amino acid decarboxylase-expressing neurons in the rat arcuate nucleus: ontogenesis and functional significance.

Authors:  M Ugrumov; V Melnikova; P Ershov; I Balan; A Calas
Journal:  Psychoneuroendocrinology       Date:  2002-07       Impact factor: 4.905

Review 6.  Monoamine transporters: from genes to behavior.

Authors:  Raul R Gainetdinov; Marc G Caron
Journal:  Annu Rev Pharmacol Toxicol       Date:  2002-09-17       Impact factor: 13.820

7.  Pramipexole increases vesicular dopamine uptake: implications for treatment of Parkinson's neurodegeneration.

Authors:  Jannine G Truong; Kristi S Rau; Glen R Hanson; Annette E Fleckenstein
Journal:  Eur J Pharmacol       Date:  2003-08-08       Impact factor: 4.432

8.  The vesicular monoamine transporter 2 (VMAT2) is expressed by normal and tumor cutaneous mast cells and Langerhans cells of the skin but is absent from Langerhans cell histiocytosis.

Authors:  Martin Anlauf; Martin K-H Schafer; Candan Depboylu; Wolfgang Hartschuh; Lee E Eiden; Guenter Kloppel; Eberhard Weihe
Journal:  J Histochem Cytochem       Date:  2004-06       Impact factor: 2.479

Review 9.  The vesicular amine transporter family (SLC18): amine/proton antiporters required for vesicular accumulation and regulated exocytotic secretion of monoamines and acetylcholine.

Authors:  Lee E Eiden; Martin K-H Schäfer; Eberhard Weihe; Burkhard Schütz
Journal:  Pflugers Arch       Date:  2003-06-24       Impact factor: 3.657

10.  Sex-dependent modulation of ethanol consumption in vesicular monoamine transporter 2 (VMAT2) and dopamine transporter (DAT) knockout mice.

Authors:  F Scott Hall; I Sora; G R Uhl
Journal:  Neuropsychopharmacology       Date:  2002-09-20       Impact factor: 7.853

View more
  58 in total

1.  Rotenone decreases intracellular aldehyde dehydrogenase activity: implications for the pathogenesis of Parkinson's disease.

Authors:  David S Goldstein; Patti Sullivan; Adele Cooney; Yunden Jinsmaa; Irwin J Kopin; Yehonatan Sharabi
Journal:  J Neurochem       Date:  2015-02-25       Impact factor: 5.372

2.  Selective monoaminergic and histaminergic circuit dysregulation following long-term HIV-1 protein exposure.

Authors:  Adam R Denton; Srimal A Samaranayake; Kristin N Kirchner; Robert F Roscoe; Shane N Berger; Steven B Harrod; Charles F Mactutus; Parastoo Hashemi; Rosemarie M Booze
Journal:  J Neurovirol       Date:  2019-05-17       Impact factor: 2.643

Review 3.  Brain dopaminergic system changes in drug addiction: a review of positron emission tomography findings.

Authors:  Haifeng Hou; Chunyan Wang; Shaowei Jia; Shu Hu; Mei Tian
Journal:  Neurosci Bull       Date:  2014-09-28       Impact factor: 5.203

4.  A case series on the heightened autonomic response due to guanfacine and amphetamine interaction.

Authors:  Edward C Gaiser; David Matuskey; Evgenia Perkins; Cynthia D'Amico; Osama Abdelghany; Sherry A McKee; Kelly P Cosgrove
Journal:  J Clin Psychopharmacol       Date:  2015-04       Impact factor: 3.153

Review 5.  Neurobiology of adolescent substance use and addictive behaviors: treatment implications.

Authors:  Christopher J Hammond; Linda C Mayes; Marc N Potenza
Journal:  Adolesc Med State Art Rev       Date:  2014-04

6.  The Concise Guide to PHARMACOLOGY 2013/14: transporters.

Authors:  Stephen P H Alexander; Helen E Benson; Elena Faccenda; Adam J Pawson; Joanna L Sharman; Michael Spedding; John A Peters; Anthony J Harmar
Journal:  Br J Pharmacol       Date:  2013-12       Impact factor: 8.739

Review 7.  Heterogeneity of dopamine release sites in health and degeneration.

Authors:  Joseph J Lebowitz; Habibeh Khoshbouei
Journal:  Neurobiol Dis       Date:  2019-11-05       Impact factor: 5.996

Review 8.  Dual-transmitter neurons: functional implications of co-release and co-transmission.

Authors:  Christopher E Vaaga; Maria Borisovska; Gary L Westbrook
Journal:  Curr Opin Neurobiol       Date:  2014-05-13       Impact factor: 6.627

Review 9.  Membrane transporters as mediators of synaptic dopamine dynamics: implications for disease.

Authors:  Kelly M Lohr; Shababa T Masoud; Ali Salahpour; Gary W Miller
Journal:  Eur J Neurosci       Date:  2016-09-02       Impact factor: 3.386

Review 10.  r

Authors:  Jacqueline S Womersley; Danyelle M Townsend; Peter W Kalivas; Joachim D Uys
Journal:  Eur J Neurosci       Date:  2018-09-24       Impact factor: 3.386

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.